Report cover image

Systemic Anti-Infectives Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 141 Pages
SKU # APRC20352530

Description

Summary

According to APO Research, The global Systemic Anti-Infectives market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Systemic Anti-Infectives is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Systemic Anti-Infectives is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Systemic Anti-Infectives is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Systemic Anti-Infectives include Alandalous, Bristol-Myers Squibb, Cipla, CR SANJIU, Dechra, Duopharma Biotech Group, MSD, PT Infion Pharma and Sumitomo Dainippon Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Systemic Anti-Infectives, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Anti-Infectives.
The Systemic Anti-Infectives market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Systemic Anti-Infectives market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Systemic Anti-Infectives Segment by Company

Alandalous
Bristol-Myers Squibb
Cipla
CR SANJIU
Dechra
Duopharma Biotech Group
MSD
PT Infion Pharma
Sumitomo Dainippon Pharma
Sun Pharma
Bayer
Bright-gene
GSK
Guangzhou Baiyunshan
Sinopharm
Harbin Pharmaceutical Group
Hailing Pharm
North China Pharmaceutical
CR Pharma
Pfizer
Luoxin Pharmaceutical
MYLAN
NOVARTIS
Johnson & Johnson
CSPC Pharmaceutical
Teva
Southwest Pharmaceutical Co., Ltd.
Chiatai Tianqing
Systemic Anti-Infectives Segment by Type

Injections
Tablets
Capsules & Pellets
Others
Systemic Anti-Infectives Segment by Application

Drugstores
Hospital
Clinic
Others
Systemic Anti-Infectives Segment by Application

Drugstores
Hospital
Clinic
Others
Systemic Anti-Infectives Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Anti-Infectives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Anti-Infectives and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Anti-Infectives.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Systemic Anti-Infectives companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

141 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Systemic Anti-Infectives by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Injections
2.2.3 Tablets
2.2.4 Capsules & Pellets
2.2.5 Others
2.3 Systemic Anti-Infectives by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Drugstores
2.3.3 Hospital
2.3.4 Clinic
2.3.5 Others
2.4 Assumptions and Limitations
3 Systemic Anti-Infectives Breakdown Data by Type
3.1 Global Systemic Anti-Infectives Historic Market Size by Type (2020-2025)
3.2 Global Systemic Anti-Infectives Forecasted Market Size by Type (2026-2031)
4 Systemic Anti-Infectives Breakdown Data by Application
4.1 Global Systemic Anti-Infectives Historic Market Size by Application (2020-2025)
4.2 Global Systemic Anti-Infectives Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Systemic Anti-Infectives Market Perspective (2020-2031)
5.2 Global Systemic Anti-Infectives Growth Trends by Region
5.2.1 Global Systemic Anti-Infectives Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Systemic Anti-Infectives Historic Market Size by Region (2020-2025)
5.2.3 Systemic Anti-Infectives Forecasted Market Size by Region (2026-2031)
5.3 Systemic Anti-Infectives Market Dynamics
5.3.1 Systemic Anti-Infectives Industry Trends
5.3.2 Systemic Anti-Infectives Market Drivers
5.3.3 Systemic Anti-Infectives Market Challenges
5.3.4 Systemic Anti-Infectives Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Systemic Anti-Infectives Players by Revenue
6.1.1 Global Top Systemic Anti-Infectives Players by Revenue (2020-2025)
6.1.2 Global Systemic Anti-Infectives Revenue Market Share by Players (2020-2025)
6.2 Global Systemic Anti-Infectives Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Systemic Anti-Infectives Head Office and Area Served
6.4 Global Systemic Anti-Infectives Players, Product Type & Application
6.5 Global Systemic Anti-Infectives Manufacturers Established Date
6.6 Global Systemic Anti-Infectives Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Systemic Anti-Infectives Market Size (2020-2031)
7.2 North America Systemic Anti-Infectives Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Systemic Anti-Infectives Market Size by Country (2020-2025)
7.4 North America Systemic Anti-Infectives Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Systemic Anti-Infectives Market Size (2020-2031)
8.2 Europe Systemic Anti-Infectives Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Systemic Anti-Infectives Market Size by Country (2020-2025)
8.4 Europe Systemic Anti-Infectives Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Systemic Anti-Infectives Market Size (2020-2031)
9.2 Asia-Pacific Systemic Anti-Infectives Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Systemic Anti-Infectives Market Size by Country (2020-2025)
9.4 Asia-Pacific Systemic Anti-Infectives Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Systemic Anti-Infectives Market Size (2020-2031)
10.2 South America Systemic Anti-Infectives Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Systemic Anti-Infectives Market Size by Country (2020-2025)
10.4 South America Systemic Anti-Infectives Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Systemic Anti-Infectives Market Size (2020-2031)
11.2 Middle East & Africa Systemic Anti-Infectives Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Systemic Anti-Infectives Market Size by Country (2020-2025)
11.4 Middle East & Africa Systemic Anti-Infectives Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Alandalous
12.1.1 Alandalous Company Information
12.1.2 Alandalous Business Overview
12.1.3 Alandalous Revenue in Systemic Anti-Infectives Business (2020-2025)
12.1.4 Alandalous Systemic Anti-Infectives Product Portfolio
12.1.5 Alandalous Recent Developments
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Information
12.2.2 Bristol-Myers Squibb Business Overview
12.2.3 Bristol-Myers Squibb Revenue in Systemic Anti-Infectives Business (2020-2025)
12.2.4 Bristol-Myers Squibb Systemic Anti-Infectives Product Portfolio
12.2.5 Bristol-Myers Squibb Recent Developments
12.3 Cipla
12.3.1 Cipla Company Information
12.3.2 Cipla Business Overview
12.3.3 Cipla Revenue in Systemic Anti-Infectives Business (2020-2025)
12.3.4 Cipla Systemic Anti-Infectives Product Portfolio
12.3.5 Cipla Recent Developments
12.4 CR SANJIU
12.4.1 CR SANJIU Company Information
12.4.2 CR SANJIU Business Overview
12.4.3 CR SANJIU Revenue in Systemic Anti-Infectives Business (2020-2025)
12.4.4 CR SANJIU Systemic Anti-Infectives Product Portfolio
12.4.5 CR SANJIU Recent Developments
12.5 Dechra
12.5.1 Dechra Company Information
12.5.2 Dechra Business Overview
12.5.3 Dechra Revenue in Systemic Anti-Infectives Business (2020-2025)
12.5.4 Dechra Systemic Anti-Infectives Product Portfolio
12.5.5 Dechra Recent Developments
12.6 Duopharma Biotech Group
12.6.1 Duopharma Biotech Group Company Information
12.6.2 Duopharma Biotech Group Business Overview
12.6.3 Duopharma Biotech Group Revenue in Systemic Anti-Infectives Business (2020-2025)
12.6.4 Duopharma Biotech Group Systemic Anti-Infectives Product Portfolio
12.6.5 Duopharma Biotech Group Recent Developments
12.7 MSD
12.7.1 MSD Company Information
12.7.2 MSD Business Overview
12.7.3 MSD Revenue in Systemic Anti-Infectives Business (2020-2025)
12.7.4 MSD Systemic Anti-Infectives Product Portfolio
12.7.5 MSD Recent Developments
12.8 PT Infion Pharma
12.8.1 PT Infion Pharma Company Information
12.8.2 PT Infion Pharma Business Overview
12.8.3 PT Infion Pharma Revenue in Systemic Anti-Infectives Business (2020-2025)
12.8.4 PT Infion Pharma Systemic Anti-Infectives Product Portfolio
12.8.5 PT Infion Pharma Recent Developments
12.9 Sumitomo Dainippon Pharma
12.9.1 Sumitomo Dainippon Pharma Company Information
12.9.2 Sumitomo Dainippon Pharma Business Overview
12.9.3 Sumitomo Dainippon Pharma Revenue in Systemic Anti-Infectives Business (2020-2025)
12.9.4 Sumitomo Dainippon Pharma Systemic Anti-Infectives Product Portfolio
12.9.5 Sumitomo Dainippon Pharma Recent Developments
12.10 Sun Pharma
12.10.1 Sun Pharma Company Information
12.10.2 Sun Pharma Business Overview
12.10.3 Sun Pharma Revenue in Systemic Anti-Infectives Business (2020-2025)
12.10.4 Sun Pharma Systemic Anti-Infectives Product Portfolio
12.10.5 Sun Pharma Recent Developments
12.11 Bayer
12.11.1 Bayer Company Information
12.11.2 Bayer Business Overview
12.11.3 Bayer Revenue in Systemic Anti-Infectives Business (2020-2025)
12.11.4 Bayer Systemic Anti-Infectives Product Portfolio
12.11.5 Bayer Recent Developments
12.12 Bright-gene
12.12.1 Bright-gene Company Information
12.12.2 Bright-gene Business Overview
12.12.3 Bright-gene Revenue in Systemic Anti-Infectives Business (2020-2025)
12.12.4 Bright-gene Systemic Anti-Infectives Product Portfolio
12.12.5 Bright-gene Recent Developments
12.13 GSK
12.13.1 GSK Company Information
12.13.2 GSK Business Overview
12.13.3 GSK Revenue in Systemic Anti-Infectives Business (2020-2025)
12.13.4 GSK Systemic Anti-Infectives Product Portfolio
12.13.5 GSK Recent Developments
12.14 Guangzhou Baiyunshan
12.14.1 Guangzhou Baiyunshan Company Information
12.14.2 Guangzhou Baiyunshan Business Overview
12.14.3 Guangzhou Baiyunshan Revenue in Systemic Anti-Infectives Business (2020-2025)
12.14.4 Guangzhou Baiyunshan Systemic Anti-Infectives Product Portfolio
12.14.5 Guangzhou Baiyunshan Recent Developments
12.15 Sinopharm
12.15.1 Sinopharm Company Information
12.15.2 Sinopharm Business Overview
12.15.3 Sinopharm Revenue in Systemic Anti-Infectives Business (2020-2025)
12.15.4 Sinopharm Systemic Anti-Infectives Product Portfolio
12.15.5 Sinopharm Recent Developments
12.16 Harbin Pharmaceutical Group
12.16.1 Harbin Pharmaceutical Group Company Information
12.16.2 Harbin Pharmaceutical Group Business Overview
12.16.3 Harbin Pharmaceutical Group Revenue in Systemic Anti-Infectives Business (2020-2025)
12.16.4 Harbin Pharmaceutical Group Systemic Anti-Infectives Product Portfolio
12.16.5 Harbin Pharmaceutical Group Recent Developments
12.17 Hailing Pharm
12.17.1 Hailing Pharm Company Information
12.17.2 Hailing Pharm Business Overview
12.17.3 Hailing Pharm Revenue in Systemic Anti-Infectives Business (2020-2025)
12.17.4 Hailing Pharm Systemic Anti-Infectives Product Portfolio
12.17.5 Hailing Pharm Recent Developments
12.18 North China Pharmaceutical
12.18.1 North China Pharmaceutical Company Information
12.18.2 North China Pharmaceutical Business Overview
12.18.3 North China Pharmaceutical Revenue in Systemic Anti-Infectives Business (2020-2025)
12.18.4 North China Pharmaceutical Systemic Anti-Infectives Product Portfolio
12.18.5 North China Pharmaceutical Recent Developments
12.19 CR Pharma
12.19.1 CR Pharma Company Information
12.19.2 CR Pharma Business Overview
12.19.3 CR Pharma Revenue in Systemic Anti-Infectives Business (2020-2025)
12.19.4 CR Pharma Systemic Anti-Infectives Product Portfolio
12.19.5 CR Pharma Recent Developments
12.20 Pfizer
12.20.1 Pfizer Company Information
12.20.2 Pfizer Business Overview
12.20.3 Pfizer Revenue in Systemic Anti-Infectives Business (2020-2025)
12.20.4 Pfizer Systemic Anti-Infectives Product Portfolio
12.20.5 Pfizer Recent Developments
12.21 Luoxin Pharmaceutical
12.21.1 Luoxin Pharmaceutical Company Information
12.21.2 Luoxin Pharmaceutical Business Overview
12.21.3 Luoxin Pharmaceutical Revenue in Systemic Anti-Infectives Business (2020-2025)
12.21.4 Luoxin Pharmaceutical Systemic Anti-Infectives Product Portfolio
12.21.5 Luoxin Pharmaceutical Recent Developments
12.22 MYLAN
12.22.1 MYLAN Company Information
12.22.2 MYLAN Business Overview
12.22.3 MYLAN Revenue in Systemic Anti-Infectives Business (2020-2025)
12.22.4 MYLAN Systemic Anti-Infectives Product Portfolio
12.22.5 MYLAN Recent Developments
12.23 NOVARTIS
12.23.1 NOVARTIS Company Information
12.23.2 NOVARTIS Business Overview
12.23.3 NOVARTIS Revenue in Systemic Anti-Infectives Business (2020-2025)
12.23.4 NOVARTIS Systemic Anti-Infectives Product Portfolio
12.23.5 NOVARTIS Recent Developments
12.24 Johnson & Johnson
12.24.1 Johnson & Johnson Company Information
12.24.2 Johnson & Johnson Business Overview
12.24.3 Johnson & Johnson Revenue in Systemic Anti-Infectives Business (2020-2025)
12.24.4 Johnson & Johnson Systemic Anti-Infectives Product Portfolio
12.24.5 Johnson & Johnson Recent Developments
12.25 CSPC Pharmaceutical
12.25.1 CSPC Pharmaceutical Company Information
12.25.2 CSPC Pharmaceutical Business Overview
12.25.3 CSPC Pharmaceutical Revenue in Systemic Anti-Infectives Business (2020-2025)
12.25.4 CSPC Pharmaceutical Systemic Anti-Infectives Product Portfolio
12.25.5 CSPC Pharmaceutical Recent Developments
12.26 Teva
12.26.1 Teva Company Information
12.26.2 Teva Business Overview
12.26.3 Teva Revenue in Systemic Anti-Infectives Business (2020-2025)
12.26.4 Teva Systemic Anti-Infectives Product Portfolio
12.26.5 Teva Recent Developments
12.27 Southwest Pharmaceutical Co., Ltd.
12.27.1 Southwest Pharmaceutical Co., Ltd. Company Information
12.27.2 Southwest Pharmaceutical Co., Ltd. Business Overview
12.27.3 Southwest Pharmaceutical Co., Ltd. Revenue in Systemic Anti-Infectives Business (2020-2025)
12.27.4 Southwest Pharmaceutical Co., Ltd. Systemic Anti-Infectives Product Portfolio
12.27.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
12.28 Chiatai Tianqing
12.28.1 Chiatai Tianqing Company Information
12.28.2 Chiatai Tianqing Business Overview
12.28.3 Chiatai Tianqing Revenue in Systemic Anti-Infectives Business (2020-2025)
12.28.4 Chiatai Tianqing Systemic Anti-Infectives Product Portfolio
12.28.5 Chiatai Tianqing Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.